Pay in 4 interest-free payments of $6.38 Learn more
Ships within 48 hours · Estimated delivery Oct 23 - Oct 28
In June 2023, Lilly reported that Orforglipron led to an average weight loss of up to 14.7% over 36 weeks in adults with obesity or overweight based on Phase II trial results
In this section, well go over some of the common questions that new patients often ask
Data from the OASIS 4 (oral semaglutide) and STEP 5 (injectable semaglutide) trials highlight similar outcomes across key endpoints
Reduce fasting window temporarily
Supply shortages have also made access unpredictable
US$ 23.18
US$ 21.19
US$ 26.91
US$ 29.79
US$ 26.24
